Send Message
801-2, Jindong Mansion, No. 536 Xueshi Road, Yinzhou, Ningbo 315100, P.R.China
Home ProductsOphthalmic Medication

Latanoprost Ophthalmic Solution 125Mcg / 2.5Ml , Ophthalmic Latanoprost Medication

Latanoprost Ophthalmic Solution 125Mcg / 2.5Ml , Ophthalmic Latanoprost Medication

  • Latanoprost Ophthalmic Solution 125Mcg / 2.5Ml , Ophthalmic Latanoprost Medication
Latanoprost Ophthalmic Solution 125Mcg / 2.5Ml , Ophthalmic Latanoprost Medication
Product Details:
Place of Origin: China
Brand Name: Newlystar
Certification: GMP
Model Number: 125mcg/2.5ml
Payment & Shipping Terms:
Minimum Order Quantity: 20000 bottles
Price: Negotiation
Packaging Details: one bottle/box
Delivery Time: 45days
Payment Terms: L/C, T/T
Supply Ability: 100, 000 bottles per day
Contact Now
Detailed Product Description
Product: Latanoprost Eye Drops Specification: 125mcg/2.5ml
Standard: In - House Packing: One Bottle/box
High Light:

ophthalmic preparations

,

ophthalmic ointment

Latanoprost Ophthalmic Solution 125Mcg / 2.5Ml , Ophthalmic Latanoprost Medication

 

 

Product : Latanoprost Eye Drops

Specification : 125mcg/2.5ml

Standard : In - house

Packing : one bottle/box

 

Description :

Latanoprost is a prostaglandin F2α analogue. Latanoprost is a colorless to slightly yellow oil that is very soluble in acetonitrile and freely soluble in acetone, ethanol, ethyl acetate, isopropanol, methanol and octanol. It is practically insoluble in water.

Latanoprost ophthalmic solution is supplied as a sterile, isotonic, buffered aqueous solution of latanoprost with a pH of approximately 6.7 and an osmolality of approximately 267 mOsmol/kg. Each mL of latanoprost ophthalmic solution contains 50 micrograms of latanoprost. Benzalkonium chloride, 0.02% is added as a preservative. The inactive ingredients are: sodium chloride, sodium phosphate dibasic (anhydrous), sodium phosphate monobasic monohydrate and water for injection. One drop contains approximately 1.5 mcg of latanoprost.

 

Indications :

Reduction of elevated intraocular pressure in patients with open angle glaucoma and ocular hypertension.

Reduction of elevated intraocular pressure in paediatric patients with elevated intraocular pressure and paediatric glaucoma.

 

Posology and method of administration :

Ocular use

Recommended dosage for adults (including the elderly):

Posology

Recommended therapy is one eye drop in the affected eye(s) once daily. Optimal effect is obtained if Latanoprost is administered in the evening.

The dosage of Latanoprost should not exceed once daily since it has been shown that more frequent administration decreases the intraocular pressure lowering effect.

If one dose is missed, treatment should continue with the next dose as normal. As with any eye drops, to reduce possible systemic absorption, it is recommended that the lachrymal sac be compressed at the medial canthus (punctal occlusion) for one minute. This should be performed immediately following the instillation of each drop.

Contact lenses should be removed before instillation of the eye drops and may be reinserted after 15 minutes.

If more than one topical ophthalmic medicinal product is being used, the medicinal products should be administered at least five minutes apart.

Paediatric population:

Latanoprost may be used in paediatric patients at the same posology as in adults. No data are available for preterm infants (less than 36 weeks gestational age). Data in age group < 1 year (4 patients) are limited.

 

Pharmacodynamics

Latanoprost is an isopropyl ester prodrug which is inactive but which becomes active after hydrolysis to the acid from. Latanoprost opthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes.

 

Mechanism of action

Latanoprost is a prostaglandin F2a analogue. Specifically, Latanoprost is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral.

Contact Details
Newlystar (Ningbo) Medtech Co.,Ltd.

Contact Person: Mr. Luke Liu

Tel: 86--57487019333

Fax: 86-574-8701-9298

Send your inquiry directly to us (0 / 3000)

Other Products